Persistence and Effectiveness of Nonbiologic Systemic Therapies for Moderate-to-severe Psoriasis in Adults: a Systematic Review

Overview

Journal Br J Dermatol

Publisher Oxford University Press

Specialty Dermatology

Date 2019 Jan 11

PMID 30628069

Citations 5

Authors

K J Mason

S Williams

Z Z N Yiu

K McElhone

D M Ashcroft

C E Kleyn

Z K Jabbar-Lopez

C M Owen

N J Reynolds

C H Smith

N Wilson

R B Warren

C E M Griffiths

Affiliations

Soon will be listed here.

Abstract

Background: The persistence and effectiveness of systemic therapies for moderate-to-severe psoriasis in current clinical practice are poorly characterized.

Objectives: To systematically review observational studies investigating the persistence and effectiveness of acitretin, ciclosporin, fumaric acid esters (FAE) and methotrexate, involving at least 100 adult patients with moderate-to-severe psoriasis, exposed to therapy for ≥ 3 months.

Methods: MEDLINE, Embase, the Cochrane Library and PubMed were searched from 1 January 2007 to 1 November 2017 for observational studies reporting on persistence (therapy duration or the proportion of patients discontinuing therapy during follow-up) or effectiveness [improvements in Psoriasis Area and Severity Index (PASI) or Physician's Global Assessment (PGA)]. This review was registered with PROSPERO, number CRD42018099771.

Results: Of 411 identified studies, eight involving 4624 patients with psoriasis were included. Variations in the definitions and analyses of persistence and effectiveness outcomes prevented a meta-analysis from being conducted. One prospective multicentre study reported drug survival probabilities of 23% (ciclosporin), 42% (acitretin) and 50% (methotrexate) at 1 year. Effectiveness outcomes were not reported for either acitretin or ciclosporin. The persistence and effectiveness of FAE and methotrexate were better characterized, but mean discontinuation times ranged from 28 to 50 months for FAE and 7·7 to 22·3 months for methotrexate. At 12 months of follow-up, three studies reported that 76% (FAE), 53% (methotrexate) and 59% (methotrexate) of patients achieved ≥ 75% reduction in PASI, and one reported that 76% of FAE-exposed patients achieved a markedly improved or clear PGA.

Conclusions: The comparative persistence and effectiveness of acitretin, ciclosporin, FAE and methotrexate in real-world clinical practice in the past decade cannot be well described due to the inconsistency of the methods used.

Citing Articles

Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023.

Lin J, Chen X, Luo M, Zhuo Q, Zhang H, Chen N Front Pharmacol. 2024; 15:1420478.

PMID: 39050749 PMC: 11267582. DOI: 10.3389/fphar.2024.1420478.

Trajectories of systemic agent use and associated depression- and anxiety-related health care costs among patients with psoriasis.

Milan R, LeLorier J, Latimer E, Brouillette M, Holbrook A, Litvinov I JAAD Int. 2022; 9:11-22.

PMID: 35996750 PMC: 9391576. DOI: 10.1016/j.jdin.2022.06.018.

Sex Differences in the Patterns of Systemic Agent use Among Patients With Psoriasis: A Retrospective Cohort Study in Quebec, Canada.

Milan R, LeLorier J, Brouillette M, Holbrook A, Litvinov I, Rahme E Front Pharmacol. 2022; 13:810309.

PMID: 35242034 PMC: 8886891. DOI: 10.3389/fphar.2022.810309.

Sex differences in factors associated with switch between systemic agents among individuals with psoriasis: A retrospective cohort study in Quebec, Canada.

Milan R, LeLorier J, Brouillette M, Holbrook A, Litvinov I, Rahme E JAAD Int. 2021; 4:79-83.

PMID: 34409398 PMC: 8361885. DOI: 10.1016/j.jdin.2021.05.008.

Psoriasis and Treatment: Past, Present and Future Aspects.

Reid C, Griffiths C Acta Derm Venereol. 2020; 100(3):adv00032.

PMID: 31971601 PMC: 9128930. DOI: 10.2340/00015555-3386.

References

Ray W . Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003; 158(9):915-20. DOI: 10.1093/aje/kwg231. View

Strober B, Siu K, Menon K . Conventional systemic agents for psoriasis. A systematic review. J Rheumatol. 2006; 33(7):1442-6. View

Dubertret L, Mrowietz U, Ranki A, van de Kerkhof P, Chimenti S, Lotti T . European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006; 155(4):729-36. DOI: 10.1111/j.1365-2133.2006.07405.x. View

Cramer J, Roy A, Burrell A, Fairchild C, Fuldeore M, Ollendorf D . Medication compliance and persistence: terminology and definitions. Value Health. 2008; 11(1):44-7. DOI: 10.1111/j.1524-4733.2007.00213.x. View

Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T . Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE). J Dtsch Dermatol Ges. 2009; 7(7):603-11. DOI: 10.1111/j.1610-0387.2009.07120.x. View

Wain E, Darling M, Pleass R, Barker J, Smith C . Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. Br J Dermatol. 2009; 162(2):427-34. DOI: 10.1111/j.1365-2133.2009.09267.x. View

Freeman K, Marum M, Bottomley J, Auland M, Jackson P, Ryttov J . A psoriasis-specific model to support decision making in practice - UK experience. Curr Med Res Opin. 2010; 27(1):205-23. DOI: 10.1185/03007995.2010.540996. View

Langham S, Langham J, Goertz H, Ratcliffe M . Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review. BMC Med Res Methodol. 2011; 11:32. PMC: 3079698. DOI: 10.1186/1471-2288-11-32. View

Dias Barbosa C, Balp M, Kulich K, Germain N, Rofail D . A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012; 6:39-48. PMC: 3262489. DOI: 10.2147/PPA.S24752. View

10.

Burden A, Warren R, Kleyn C, McElhone K, Smith C, Reynolds N . The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Dermatol. 2012; 166(3):545-54. DOI: 10.1111/j.1365-2133.2012.10835.x. View

11.

Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo J . Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012; 148(4):463-70. DOI: 10.1001/archdermatol.2011.2768. View

12.

Gelfand J, Wan J, Callis Duffin K, Krueger G, Kalb R, Weisman J . Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012; 148(4):487-94. PMC: 3476943. DOI: 10.1001/archdermatol.2012.370. View

13.

Christophers E, Segaert S, Milligan G, Molta C, Boggs R . Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. J Dermatolog Treat. 2012; 24(3):193-8. DOI: 10.3109/09546634.2012.697112. View

14.

Inzinger M, Weger W, Heschl B, Salmhofer W, Quehenberger F, Wolf P . Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions. J Eur Acad Dermatol Venereol. 2012; 27(7):861-6. DOI: 10.1111/j.1468-3083.2012.04596.x. View

15.

Yeung H, Wan J, Van Voorhees A, Callis Duffin K, Krueger G, Kalb R . Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2012; 68(1):64-72. PMC: 3488143. DOI: 10.1016/j.jaad.2012.06.035. View

16.

Borghi A, Corazza M, Mantovani L, Bertoldi A, Giari S, Virgili A . Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients. Int J Dermatol. 2012; 51(12):1512-6. DOI: 10.1111/j.1365-4632.2012.05571.x. View

17.

Norlin J, Steen Carlsson K, Persson U, Schmitt-Egenolf M . Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice. Dermatology. 2013; 225(4):326-32. DOI: 10.1159/000345715. View

18.

Singal A, Higgins P, Waljee A . A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014; 5:e45. PMC: 3912314. DOI: 10.1038/ctg.2013.13. View

19.

Ismail N, Collins P, Rogers S, Kirby B, Lally A . Drug survival of fumaric acid esters for psoriasis: a retrospective study. Br J Dermatol. 2014; 171(2):397-402. DOI: 10.1111/bjd.12849. View

20.

Svedbom A, Dalen J, Mamolo C, Cappelleri J, Petersson I, Stahle M . Treatment patterns with topicals, traditional systemics and biologics in psoriasis - a Swedish database analysis. J Eur Acad Dermatol Venereol. 2014; 29(2):215-223. DOI: 10.1111/jdv.12494. View